Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation
ARPA-H PROSPR program to support accelerated development of LNS8801 to promote healthy aging
HADDONFIELD, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Linnaeus Therapeutics, Inc., a privately held company focused on the development and commercialization of small molecule therapeutics for diseases of aging, today announced it has been awarded a contract of up to $22 million from the Advanced Research Projects Agency for Health (ARPA-H). As part of the PROactive Solutions for Prolonging Resilience (PROSPR) program, Linnaeus will advance its lead drug-candidate, LNS8801, for the preservation of healthspan.
This award will support a multiphase translational PROSPR research program designed to accelerate the development and evaluation of interventions that maintain physical and cognitive function and delay age-associated functional decline. The program will assess whether activation of the G protein-coupled estrogen receptor (GPER) with LNS8801 can preserve Intrinsic Capacity, defined as the integrated physical and cognitive abilities that underpin independence and resilience later in life.
“Real-world data suggesting that women experience more favorable outcomes compared to men across multiple diseases of aging inspires our work at Linnaeus,” said Christopher Natale, PhD, Co-Founder and Chief Scientific Officer of Linnaeus Therapeutics and Principal Investigator on the award. “The PROSPR program will support studies that directly assess whether LNS8801 can preserve Intrinsic Capacity and improve healthspan.”
LNS8801 is a first-in-class, only-in-class, oral, selective agonist of GPER with clinical evidence of biological activity across multiple physiological systems implicated in age-related functional decline and cancer. Under the PROSPR program, Linnaeus will conduct preclinical aging studies followed by a randomized clinical study in healthy older adults. These efforts will incorporate functional assessments, physiological and molecular biomarkers, and emerging measures of biological aging to enable efficient evaluation of healthspan-related outcomes.
The program builds on prior clinical experience with LNS8801 in oncology, where more than 100 patients have been treated in a phase 1/2 study. In this study, LNS8801 demonstrated an exceptional safety and tolerability profile. Clinical data strongly suggest improved survival in patients with cancer, as well as clinically meaningful improvements in cardiometabolic measures, including LDL cholesterol, systolic blood pressure, Hb1AC, and weight loss. These data support further investigation of LNS8801 in multiple diseases of aging.
“LNS8801 has a mechanism of action expected to provide benefits in multiple organ systems,” said Patrick Mooney, MD, Chief Executive Officer of Linnaeus Therapeutics. “ARPA-H’s evaluation of our data and subsequent award validates the promise of LNS8801 to potentially prevent diseases of aging and will enable a rigorous program to translate that promise into clinically meaningful improvements in healthspan-predictive outcomes.”
“Since cardiometabolic health naturally declines with age, the preliminary data suggesting LNS8801 improves these in humans is compelling,” says Andrew Brack, ARPA-H Program Manager and creator of the PROSPR program. “That's why we’re excited to see whether this treatment will improve Intrinsic Capacity and healthspan.”
This ARPA-H–supported work could establish a new preventive approach to medicine, preserving function and independence, rather than treating age-related diseases after decline has occurred. There are significant potential benefits for public health and healthcare sustainability.
About LNS8801
LNS8801 is an orally bioavailable, highly selective agonist of the G protein-coupled estrogen receptor (GPER). In preclinical studies, GPER activation by LNS8801 has demonstrated activity across multiple biological pathways relevant to cancer, cardiometabolic health, inflammation, neurodegeneration, and tissue resilience.
In ongoing clinical studies in patients with advanced cancers, LNS8801 monotherapy has been safe and well tolerated, with no dose-limiting toxicities observed. Clinical data have demonstrated target engagement and evidence of clinical activity, and a predictive biomarker associated with response has been identified. These findings, together with emerging cardiometabolic observations in patients treated with LNS8801, support continued evaluation of LNS8801 beyond oncology.
About Linnaeus Therapeutics
Linnaeus Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule therapeutics targeting G protein-coupled receptors. The company was founded based on discoveries originating at the University of Pennsylvania and launched in partnership with the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI). Linnaeus is supported by Kairos Ventures, Penn Medicine Co-Investment Fund at the University of Pennsylvania, and GenHenn Capital. Linnaeus is advancing LNS8801 across oncology and emerging healthspan-related indications through an integrated translational and clinical development strategy.
Media Contact:
Sarah Hall
6 Degrees
(215) 313-5638
shall@6degreespr.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
